What You Need to Know about Nipah Virus
Share this article
What is Nipah Virus and How Does It Spread?
Nipah virus infection is a viral zoonotic disease caused by the Nipah virus (NiV) from the genus Henipavirus. Fruit bats, also known as flying foxes, are the primary zoonotic host and can transmit the virus to humans and animals—particularly livestock such as pigs and horses.
The virus can spread to people through consumption of raw date palm sap and fruit that has been contaminated with bat secretions (saliva, urine). Transmission can also occur through close contact with an infected animal or its bodily fluids.
Once infected, person-to-person spread is possible with close contact and through nasal and respiratory secretions, blood, and urine. When person-to-person transmission occurs, it happens most commonly in health care settings or in caretakers of NiV-infected patients. Patients with respiratory symptoms are more likely to spread NiV.
Nipah Virus Infection Outbreaks
Nipah virus (NiV) is named after the village in Malaysia where the first cases were identified in 1998. The outbreak resulted in more than 300 cases and 100 deaths in pig farm workers in Malaysia and Singapore. Since then, nearly annual outbreaks have occurred in Southeast Asia (CDC, https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON442, accessed 2/10/23), primarily in Bangladesh and eastern India. As of February 2023, there have been 10 cases, including 7 deaths, reported in Bangladesh this year.
Signs and Symptoms of Nipah Virus Infection
Nipah Virus (NiV) infection can cause disease that ranges from mild to severe, including encephalitis, and potentially death.
Symptoms typically appear within 4-14 days of exposure to the virus. Presenting symptoms may initially include one or more of the following:
- Fever
- Headache
- Cough
- Sore throat
- Difficulty breathing
- Vomiting
Clinical Care for Patients Infected with Nipah Virus
Diagnosis of Nipah virus (NiV) infection can be difficult due to its non-specific early symptoms. NiV infection should be considered in people with symptoms consistent with infection who have been in areas where outbreaks are common (Bangladesh, India, Malaysia, Singapore) and in those who report contact with raw date juice, fallen fruit, bats, livestock, or sick animals.
Early detection is critical to increase chances of survival, prevent further transmission, and protect the safety of health care workers.
Severe symptoms may develop rapidly and include:
- Disorientation, drowsiness, or confusion
- Seizures
- Coma
- Brain swelling (encephalitis)
- Acute respiratory distress
Case fatality rates in previous outbreaks range from 40-75 percent. Survivors of NiV infection may have recurrent seizures and personality changes. Dormant or latent infections have also been reported months or years after exposure.
While there are no licensed treatments available for NiV infection, the monoclonal antibody m102.4 has undergone Phase 1 testing and has been used under compassionate care for individuals exposed to NiV and the related Hendra virus. The antiviral Veklury (remdesivir) has been shown to lessen disease severity in a non-human primate model of disease. Learn more about treatment options. (NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8483238/, accessed 2/10/23)
Treatment is otherwise limited to supportive care, including rest, hydration, and treatment of symptoms as they occur.
Are you prepared to treat a patient infected with NiV? NETEC’s free course “Special Pathogen of Concern,” designed for health care professionals and emergency responders, can help you to prepare for a special pathogen event. Learn more and sign up now.
Recommended Personal Protective Equipment (PPE)
The recommended PPE for health care workers caring for patients suspected or confirmed to be infected with Nipah virus (NiV) includes contact and droplet precautions:
- Medical or surgical mask: increased respiratory protection such as a fit-tested N95 respirator or higher may be utilized depending upon patient condition, duration of contact, and clinical interventions required.
- Isolation gown: choose the level of gown based on risk; AAMI PB70 Level 1 –3 have increasing levels of resistance to fluids, and Level 4 is tested for viral penetration.
- Gloves: non-sterile medical exam gloves; double gloving and the use of extended cuff gloves may be advised.
- Eye protection: goggles or safety glasses that provide a barrier from all sides; or a full-face shield that extends past the sides of the face and to the chin.
Facilities with biocontainment units may choose to utilize full coverage ensembles as part of unit protocols.
Infection Control Measures for Nipah Virus Infection
Because Nipah virus (NiV) can spread from person-to-person, the CDC recommends standard infection control practices (CDC, https://www.cdc.gov/vhf/nipah/prevention/index.html, Accessed 2/10/2023) to prevent hospital-acquired infections.
Like Ebola virus, NiV is a Tier 1 enveloped virus—the easiest to inactivate with the right disinfectant. To disinfect surfaces, refer to the EPA Q-List for recommended disinfectants. (EPA, https://www.epa.gov/pesticide-registration/disinfectants-emerging-viral-pathogens-evps-list-q, 2/10/23)
Waste generated in the care of patients with NiV infection, including laboratory waste and used PPE, is considered Category A waste, and should be handled in accordance with local, state, and federal guidelines. See the guidelines for managing solid waste contaminated with a Category A Infectious Substance.
Testing for Nipah Virus Infection
Laboratory testing for Nipah virus (NiV) is available through the CDC’s Viral Special Pathogen’s Branch (CDC. https://www.cdc.gov/ncezid/dhcpp/vspb/specimens.html, Accessed 2/10/2023). Pre-approval is required, so work with your local public health department for the appropriate specimen type.
Clinical specimens suspected of containing NiV are considered Category A when shipping.
Is your facility ready to treat a patient with NiV infection? NETEC offers comprehensive self-assessments for hospitals and EMS agencies to help evaluate your operational readiness to manage a special pathogen event.
Additional Resources
Evaluation and comparison of three virucidal agents on inactivation of Nipah virus (NETEC, https://repository.netecweb.org/items/show/1745, Accessed 2024)
Recent advances in combating Nipah virus (NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8483238/, accessed 2/10/23)
Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
Get Expert Assistance
Ask a NETEC expert a question or request free services for your facility.
Find Resources
Explore special pathogen resources created and curated by NETEC experts.
Authors
Dr. Corri Levine, PhD, MS, MPH, is a virologist specializing in high-containment pathogens and the program manager for the Special Pathogens Excellence in Clinical Treatment, Readiness, & Education program (SPECTRE) at the University of Texas Medical Branch. Dr. Levine works at the intersection of research, clinical care, and public health ensuring knowledge is passed between these sectors for the betterment of the patient and community. Dr. Levine is an active member of SPRN and is leading the development of a clinical biorepository for the study of special pathogens.
Jill Morgan, RN, BSN, is a nurse at Emory University Hospital and a site manager of Emory’s Serious Communicable Disease Unit. At NETEC, Jill leads the personal protective equipment (PPE) work group, developing education emphasizing the importance of early identification and isolation of patients infected with potential pathogens. She is also a member of ASTM and AAMI.
